Ampio Pharmaceuticals, Inc. (AMPE) Announces Participation at the UBS Global Healthcare Conference
5/13/2013 6:43:35 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Completes Enrollment in Run-In SPRING Study of Ampion in Osteoarthritis of the Knee
4/25/2013 10:55:44 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Receives FDA Clearance to Initiate Clinical Trial of Ampion™ for the Treatment of Osteoarthritis of the Knee: Patient Treatments have Begun
4/2/2013 9:23:41 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Receives FDA Acceptance of its Patient Outcome for Premature Ejaculation (POPE) Questionnaire, Paving the Way for its US Pivotal Trial on Zertane™
3/11/2013 10:04:16 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Clinical Trial of Optina™ in Diabetic Macular Edema (DME): First Patient Dosed
2/27/2013 9:34:31 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Modifies Ampion™ IND for Osteoarthritis of the Knee to Include a Dose Escalation Run-In Study and Prepares to Launch Pivotal Clinical Trial
2/25/2013 11:11:29 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Forms Luoxis Diagnostics to Commercialize ORP Technology
2/11/2013 9:09:36 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Announces Active IND for Optina™ for the Treatment of Diabetic Macular Edema (DME)
1/22/2013 9:36:44 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) Announces Participation at Upcoming Investor Conference
1/22/2013 6:13:40 AM
More...
|
Ampio Pharmaceuticals, Inc. (AMPE) (AMPE) Announces Appointment of Josh Disbrow as Chief Operating Officer Effective December 15, 2012
11/28/2012 8:33:58 AM
More...
|
|